Stoke Therapeutics (NASDAQ:STOK) CFO Thomas Leggett Sells 2,382 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) CFO Thomas Leggett sold 2,382 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $74,651.88. Following the completion of the sale, the chief financial officer directly owned 10,172 shares of the company’s stock, valued at approximately $318,790.48. This represents a 18.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Thomas Leggett also recently made the following trade(s):

• On Tuesday, March 17th, Thomas Leggett sold 2,196 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total value of $72,489.96.

Stoke Therapeutics Stock Up 3.7%

NASDAQ:STOK opened at $34.41 on Friday. The company has a market cap of $2.04 billion, a PE ratio of 51.46 and a beta of 1.07. The business’s 50 day moving average is $32.60 and its two-hundred day moving average is $29.93. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $40.22.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $26,000. Harbour Investments Inc. boosted its position in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares during the period. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics during the third quarter worth approximately $41,000. BNP Paribas Financial Markets grew its holdings in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares in the last quarter.

Key Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Several firms reaffirmed or raised bullish views and price targets on STOK, supporting buying interest — Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
• Positive Sentiment: BTIG reaffirmed a Buy rating and set a $39 price target, signaling notable upside vs. recent levels and likely attracting momentum buyers. BTIG Research reaffirmation (Benzinga)
• Positive Sentiment: Wedbush raised its price target to $38 and Needham published a bullish outlook for strong price appreciation—additional analyst support that can underpin the rally. Wedbush Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $38.00
• Positive Sentiment: Coverage of Stoke’s experimental program highlights broader clinical potential beyond seizure control — reporting suggests the drug aims to reverse developmental loss in Dravet syndrome, which supports longer‑term value. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces examined a recent sharp pullback and the drivers behind it — useful context for traders but not new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
• Negative Sentiment: Multiple insiders (including the CFO, general counsel and other executives) disclosed sizable sales across March 17–19, trimming positions by double-digit percentages — insider selling can weigh on sentiment and prompt investor caution. Representative filing: SEC Form 4 (Jonathan Allan)

Wall Street Analyst Weigh In

A number of research firms have commented on STOK. UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a report on Monday, December 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research report on Thursday. Guggenheim began coverage on shares of Stoke Therapeutics in a report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price target for the company. Finally, Chardan Capital reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.